Supplementary Material for: EFFICACY OF CO-MEDICATIONS IN PATIENTS WITH ALCOHOLIC LIVER DISEASE (ALD)

Background: Alcoholic liver disease (ALD) is still increasing and lead to acute liver injury but also liver cirrhosis and subsequent complications such as liver failure or hepatocellular carcinoma (HCC). As most patients fail to achieve alcohol abstinence, it is essential to identify alternative treatment options in order to improve the outcome of ALD patients. Methods: Evaluating two large cohorts of patients with ALD form the USA and Korea with a total of 12,006 patients. We investigated the effect in survival of aspirin, metformin, metoprolol, dopamine and dobutamine drugs in patients with ALD between 2000 and 2020. Patient data were obtained through the “The Observational Health Data Sciences and Informatics (OHDSI) consortium”, an open-source, multi-stakeholder, and interdisciplinary collaborative effort. Results: The use of aspirin (p=0.000, p=0.000), metoprolol (p=0.002, p=0.000) and metformin (p=0.000, p=0.000) confers a survival benefit for both AUSOM and NY treated cohorts. Need of catecholamines dobutamine (p=0.000, p=0.000) and dopamine (p=0.000, p=0.000) were strongly indicative of poor survival. B-blocker treatment with Metoprolol (p=0.128, p=0.196) or Carvedilol (p=0.520, p=0.679) were not shown to be protective in any of the female subgroups. Conclusion: Overall, our data fill a large gap of long-term, real-world data on patients with ALD, confirming an impact of metformin, ASA and β-blockers on ALD patient´s survival. However, gender and ethnic background lead to diverse efficacy in those patients.